Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer
AUTOR(ES)
Chan, June M.
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2720077Documentos Relacionados
- Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
- Radical prostatectomy for high-risk prostate cancer | Opinion: YES
- Radical prostatectomy for high-risk prostate cancer | Opinion: NO
- INTERVENING ON HIGH-RISK OR VULNERABLE POPULATIONS?
- A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
